RNA interference suppression of neurodegenerative diseases and methods of use

Patent metadata

Field	Value
Publication number	US-10072264-B2
Application number	US-201615395993-A
Country	US
Kind code	B2
Filing date	Dec 30, 2016
Priority date	Aug 5, 2002
Publication date	Sep 11, 2018
Grant date	Sep 11, 2018

Abstract

The present invention is directed to small interfering RNA molecules (siRNA) targeted against nucleic acid sequence that encodes huntingtin or ataxin-1, and methods of using these siRNA molecules.

First claim

What is claimed is:

1. An isolated RNA duplex comprising a first strand of RNA and a second strand of RNA, wherein the first strand comprises at least 15 contiguous nucleotides encoded by SEQ ID NO:97, and wherein the second strand is complementary to at least 12 contiguous nucleotides of the first strand.

2. The RNA duplex of claim 1 , wherein the duplex is between 15and 30 base pairs in length.

3. The RNA duplex of claim 1 , wherein the duplex is between 19 and 25 base pairs in length.

4. The RNA duplex of claim 1 , wherein the first and/or second strand further comprises an overhang region.

5. The RNA duplex of claim 1 , wherein the first and/or second strand further comprises a 3′ overhang region, a 5′ overhang region, or both 3′ and 5′ overhang regions.

6. The RNA duplex of claim 4 , wherein the overhang region is from 1 to 10nucleotides in length.

7. The RNA duplex of claim 1 , wherein the first strand and the second strand are operably linked by means of an RNA loop strand to form a hairpin structure comprising a duplex structure and a loop structure.

8. The RNA duplex of claim 7 , wherein the loop structure contains from 4 to 10nucleotides.

9. The RNA duplex of claim 7 , wherein the loop structure contains 4, 5 or 6nucleotides.

10. The RNA duplex of claim 7 , wherein the loop structure corresponds to SEQ ID NO:61 or SEQ ID NO:64.

11. An expression cassette comprising a nucleic acid encoding at least one strand of the RNA duplex of claim 1 .

12. The expression cassette of claim 11 , further comprising a promoter.

13. The expression cassette of claim 12 , wherein the promoter is a regulatable promoter.

14. The expression cassette of claim 12 , wherein the promoter is a constitutive promoter.

15. The expression cassette of claim 12 , wherein the promoter is a CMV, RSV, pol II or pol III promoter.

16. The expression cassette of claim 11 , wherein the expression cassette further comprises a polyadenylation signal.

17. The expression cassette of claim 16 , wherein the polyadenylation signal is a synthetic minimal polyadenylation signal.

18. The expression cassette of claim 11 , further comprising a marker gene.

19. A vector comprising the expression cassette of claim 11 .

20. A method of suppressing the accumulation of huntingtin or ataxin-1 in a cell comprising introducing into the cell in an amount sufficient to suppress accumulation of huntingtin or ataxin-1 in the cell
(a) a ribonucleic acid (RNA) duplex, wherein the RNA duplex comprises a first strand of RNA and a second strand of RNA, wherein the first strand comprises at least 15contiguous nucleotides encoded by SEQ ID NO:97 or SEQ ID NO:100, and wherein the second strand is complementary to at least 12 contiguous nucleotides of the first strand; or
(b) a vector comprising an expression cassette comprising a nucleic acid encoding a first strand of RNA and a second strand of RNA of an RNA duplex, wherein the first strand comprises at least 15 contiguous nucleotides encoded by SEQ ID NO:97 or SEQ ID NO:100.

21. The method of claim 20 , wherein the first strand comprises at least 15 contiguous nucleotides encoded by SEQ ID NO:97.

22. The method of claim 20 , wherein the first strand comprises at least 15 contiguous nucleotides encoded by SEQ ID NO:100.

23. The method of claim 20 , wherein the duplex is between 15 and 30 base pairs in length.

24. The method of claim 20 , wherein the duplex is between 19 and 25 base pairs in length.

25. The method of claim 20 , wherein the first and/or second strand further comprises an overhang region.

26. The method of claim 20 , wherein the first and/or second strand further comprises a 3′ overhang region, a 5′ overhang region, or both 3′ and 5′ overhang regions.

27. The method of claim 25 , wherein the overhang region is from 1 to 10 nucleotides in length.

28. The method of claim 20 , wherein the first strand and the second strand are operably linked by means of an RNA loop strand to form a hairpin structure comprising a duplex structure and a loop structure.

29. The method of claim 28 , wherein the loop structure contains from 4 to 10nucleotides.

30. The method of claim 28 , wherein the loop structure contains 4, 5 or 6nucleotides.

31. The method of claim 28 , wherein the loop structure corresponds to SEQ ID NO:61 or SEQ ID NO:64.

32. The method of claim 20 , wherein the expression cassette further comprises a promoter.

33. The method of claim 32 , wherein the promoter is a regulatable promoter.

34. The method of claim 32 , wherein the promoter is a constitutive promoter.

35. The method of claim 32 , wherein the promoter is a CMV, RSV, pol II or pol III promoter.

36. The method of claim 20 , the expression cassette further comprises a polyadenylation signal.

37. The method of claim 36 , wherein the polyadenylation signal is a synthetic minimal polyadenylation signal.

38. The method of claim 20 , wherein the vector further comprises a marker gene.

Assignees

• Univ Iowa Res Found

Inventors

• Davidson Beverly L
• Xia Haibin
• Mao Qinwen
• Paulson Henry
• Boudreau Ryan
• Harper Scott

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• C12N2310/53

  partially self-complementary or closed · CPC title

• C12N2799/022

  where the vector is derived from an adenovirus · CPC title

• C12N2799/025

  where the vector is derived from a parvovirus · CPC title

• C12N15/113 Primary

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title